The Enhanced Liver Fibrosis (ELF) is the first prognostic tool for patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to be granted De Novo marketing authorization.

TARRYTOWN, N.Y.--(BUSINESS WIRE)--The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive ...

Disclaimer: The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed. In the U.S., the ELF Test is indicated as a ...

At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...

Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...

Siemens is launching a new diagnostic amid a rise in liver damage cases caused by so-called fatty-liver disease. (Database Center for Life Science/CC BY-SA 2.1) () Siemens is launching its Enhanced ...

Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin).